by 
Advanced glycation end products (AGEs) refer to compounds formed by non-enzymatic glycation and oxidation of proteins and lipids over time. AGEs accumulate in tissues and organs with age and smoking. Chronic elevated levels of AGEs and their interaction with receptors for AGEs (RAGEs) play a significant role in inflammation and oxidative stress related pathogenesis of diabetes and its complications. AGEs are also associated with several other chronic diseases, including cardiovascular disease, chronic kidney disease, neurological disorders and cancer. The global AGEs market is primarily driven by the growing diabetic and aging population coupled with increasing investments in R&D activities.
The Global Advanced Glycation End Products Market is estimated to be valued at US$ 3,469.95 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the Advanced Glycation End Products are Sensoris Inc, Geron Corp, Amadix LLC, Canon Babcock Inc.
The market offers significant growth opportunities owing to increasing collaborations between players for new product development and geographical expansion. Moreover, growing focus on early diagnosis of diabetes and increasing approvals of AGE breakers are expected to present attractive prospects.
Continuous research and development activities are expected to generate demand for nanoemulsions in the pharmaceutical industry. In June 2019, a team of engineers from the MIT announced that they are developing a method of converting liquid nanoemulsions into solid gels.
Market drivers
The increasing prevalence of diabetes and aging population globally are primary factors augmenting the demand for diagnostic tests and therapeutic agents for management of AGE related diseases. It is estimated that nearly 1 in 2 Americans will either have diabetes or prediabetes by 2050. Additionally, continuous advancements in drug delivery systems have improved efficacy and safety of AGE breaker therapeutics.
Challenges in the Advanced Glycation End Products Market
The Advanced Glycation End Products market is facing challenges due to rising health concerns associated with diabetes and obesity worldwide. Diabetes and obesity are primary factors contributing to the accumulation of AGEs in the body. According to the World Health Organization, diabetes was the seventh leading cause of death in 2016, globally. The number of adults living with diabetes has nearly quadrupled since 1980 to 422 million today. Obesity rates are also increasing significantly. These rising health issues lead to the increased accumulation of AGEs in patients, thereby augmenting the demand for effective AGEs inhibitors and retardants. However, extensive clinical trials and research activities need to be undertaken to realize the potential benefits of anti-AGEs therapeutics. The presence of many alternative treatment options is another challenge.
SWOT ANALYSIS
Strength: Accumulating research results proving association between AGEs and several lifestyle diseases.
Weakness: High costs associated with research and development of innovative anti-AGEs therapies.
Opportunity: Untapped growth prospects in emerging nations due to rising healthcare expenditures.
Threats: Stringent regulatory framework for approval of new drugs.
The United States holds the largest share of the advanced glycation end products market owing to the increasing prevalence of chronic disorders in the region. According to Centers for Disease Control and Prevention (CDC), six in ten adults in the US have a chronic disease and four in ten adults have two or more chronic diseases. Furthermore, nearly half of all American adults suffer from obesity. These factors significantly contribute to the accumulation of AGEs, thereby propelling the demand for AGEs inhibitors and retardants.
The Asia Pacific region is poised to register the fastest growth over the forecast period owing to improving healthcare infrastructure, rising medical tourism, increasing disposable incomes, and growing focus of international players. Rising diabetes and obesity rates due to changing lifestyles and dietary patterns are also boosting the regional market. For instance, China and India have the highest number of diabetics worldwide.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
